Comparison of moxalactam and gentamicin in the treatment of complicated urinary tract infections

Penn, Robert G.; Preheim, Laurel C.; Sanders, Christine C.; Giger, D K

doi:10.1128/aac.24.4.494

Cited by 14 publications

(9 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nephrotoxicity occurred in 9% of patients treated with gentamicin, a percentage comparable to those of other studies with this antimicrobial agent (11,13,14).…”

Section: Discussionsupporting

confidence: 62%

“…Seven (24%) of these were on an intermittent catheterization program without bladder irrigation, and three were colonized with S. faecalis. Although most researchers relate enterococcal superinfection and colonization to the use of P-lactam antibiotics (1,3,11,13), others have also shown that concomitant anatomical or physiological abnormalities of the urinary tract may have a role in the acquisition of the infection (4,9,12).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Carumonam (Ro 17-2301; AMA-1080) compared with gentamicin for treatment of complicated urinary tract infections

Hoepelman¹,

Bakker²,

Verhoef³

1988

Antimicrob Agents Chemother

View full text Add to dashboard Cite

“…Nephrotoxicity occurred in 9% of patients treated with gentamicin, a percentage comparable to those of other studies with this antimicrobial agent (11,13,14).…”

Section: Discussionsupporting

confidence: 62%

Section: Discussionmentioning

confidence: 99%

Carumonam (Ro 17-2301; AMA-1080) compared with gentamicin for treatment of complicated urinary tract infections

Hoepelman¹,

Bakker²,

Verhoef³

1988

Antimicrob Agents Chemother

View full text Add to dashboard Cite

“…These infections contribute to patient mortality (10) and health-care costs (5). MOX and CAZ compare favorably with aminoglycosides in this setting (2,9). In our study, CAZ produced higher cure and lower relapse rates than did MOX for infections due to urinary pathogens susceptible to both antibiotics.…”

mentioning

confidence: 63%

“…One patient with Pseudomonas aeruginosa (not serotypable) treated with MOX became reinfected with a second strain of Pseudomonas aeruginosa (serotype 11) which was resistant to MOX, cefotaxime, ceftriaxone, carbenicillin, (9). These infections contribute to patient mortality (10) and health-care costs (5).…”

mentioning

confidence: 99%

Randomized, double-blind comparison of ceftazidime and moxalactam in complicated urinary tract infections

Horowitz¹,

Preheim²,

Safranek³

et al. 1985

Antimicrob Agents Chemother

Self Cite

View full text Add to dashboard Cite

Sixty-seven patients with complicated urinary tract infections were randomized in double-blind fashion to ceftazidime or moxalactam (MOX) of resistance in Pseudomonas aeruginosa during therapy with MOX has been reported (11). Therefore, a Pseudomonas isolate signalled the pharmacist to increase the dose to 2 g every 12 h for patients randomized to MOX. The usual length of treatment was 7 days. Four patients were treated for 9.5, 10, 10, and 11.5 days, respectively. One patient had pyelonephritis; the others had therapy extended through the performance of cystoscopy.Nosocomial infection was defined as onset of symptoms after more than 48 h in the hospital.Open study. A patient was considered for a nonblinded protocol with CAZ when the infecting organism was resistant to MOX. Enrollment, treatment, and follow-up were otherwise identical with the randomized study.Laboratory studies. Urine cultures and susceptibilities (1) were repeated after 2 to 4 days of therapy and at 5 to 9 days posttherapy. When

show abstract

“…The ability of aminoglycosides to accumulate in the renal parenchyma, especially the medulla of the kidney, may offer therapeutic potential for the treatment of kidney infections (3). In adults, these antibiotics are commonly used for the therapy of severe urinary tract infections (UTIs) (25). In childhood, the management of UTI differs according to the age of the patient and the site of infection.…”

mentioning

confidence: 99%

Comparison of 5 milligrams of netilmicin per kilogram of body weight once daily versus 2 milligrams per kilogram thrice daily for treatment of gram-negative pyelonephritis in children

Viganò

Principi

Brivio

et al. 1992

Antimicrob Agents Chemother

View full text Add to dashboard Cite

The efficacy and safety of netilmicin, 5 mg/kg of body weight once daily or 2 mg/kg thrice daily for 10 days, for the treatment of gram-negative pyelonephritis in children were compared in a prospective, randomized trial. Explicit criteria were used to define the site of infection, treatment outcome, and adverse effects.Netilmicin was given to 74 children once daily and to 70 children three times daily. At 1 week posttreatment, 73 (99%) of 74 children treated with netilmicin once daily and 70 (100%) of 70 children treated with netilmicin three times daily were cured. At 4 weeks posttreatment, no relapse was detected and the rate of reinfection was essentially identical in the two treatment groups. Peak serum netilmicin concentrations were higher in patients given the once-daily regimen, whereas a higher trough level was detected in patients given the three-times-daily regimen. Nephrotoxicity, which was defined as an increase in the serum creatinine level of >0.3 mg/dl over the baseline, was rare (3%) and reversible and occurred regardless of the treatment regimen. Ototoxicity, which was assessed by pure-tone audiometry (250 to 8,000 Hz) and brain stem-evoked response (6,000 Hz), occurred in 2 of 32 children who were evaluated. In these two children, who were given the once-daily regimen, wave V was not evokable monolateraily below 25 and 40 dB normal hearing level, respectively. Thus, it may be possible to treat childhood pyelonephritis with netilmicin once daily. However

show abstract

Comparison of moxalactam and gentamicin in the treatment of complicated urinary tract infections

Cited by 14 publications

References 16 publications

Carumonam (Ro 17-2301; AMA-1080) compared with gentamicin for treatment of complicated urinary tract infections

Carumonam (Ro 17-2301; AMA-1080) compared with gentamicin for treatment of complicated urinary tract infections

Randomized, double-blind comparison of ceftazidime and moxalactam in complicated urinary tract infections

Comparison of 5 milligrams of netilmicin per kilogram of body weight once daily versus 2 milligrams per kilogram thrice daily for treatment of gram-negative pyelonephritis in children

Contact Info

Product

Resources

About